Evidence check: TCF7L2 in the context of Wechseljahre

The question about TCF7L2 in the context of menopause is scientifically valid, but the evidence is thin. TCF7L2 variants (e.g., rs7903146) are strongly associated with type 2 diabetes risk, and menopause involves hormonal shifts that increase diabetes susceptibility. Some studies suggest that TCF7L2 carriers may have higher postmenopausal glucose intolerance, but data are inconsistent and mostly from subgroup analyses. No specific guidelines recommend TCF7L2 screening during menopause. The effect is moderate and heavily modified by lifestyle (diet, exercise). A genetic test alone is not clinically actionable; metabolic markers (fasting glucose, HbA1c, HOMA-IR) are more relevant. Beware of overinterpretation by direct-to-consumer tests. Evidence: mixed – strong for diabetes, weak for menopause-specific context.